Biomarker Panel for Accurate Prostate Cancer BCR Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostate cancer screening tools lack accuracy in detecting biochemical recurrence (BCR), which is predictive of distant metastases and mortality, necessitating improved diagnostic methods for early detection.
Innovation Solution
The use of biomarkers such as tenascin C, apolipoprotein A-IV, and 1-methyladenosine, alone or in combination with tumor stage and Gleason score, to diagnose and monitor BCR in prostate cancer by comparing marker levels in biological samples against predetermined thresholds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional screening tools (PSA) are used for detecting BCR, then the diagnostic process is simple and widely available, but the accuracy and reliability of detection is insufficient
Solution Approach 1:
The patent combines multiple biomarkers (tenascin C, apolipoprotein A-IV, 1-methyladenosine, phosphatidic acid) with traditional clinical features (tumor stage, Gleason score) to create a comprehensive diagnostic panel. This merging of multiple detection targets enhances diagnostic accuracy for biochemical recurrence while maintaining a unified testing framework.
Solution Approach 2:
The diagnostic system uses a composite biomarker panel where multiple molecular markers work synergistically to detect BCR. The combination of proteins, metabolites, and lipids creates a more robust diagnostic signal than any single marker alone, improving reliability without requiring multiple separate complex tests.
2Measurement precision
If multiple biomarkers are combined to improve detection accuracy, then diagnostic reliability improves, but the complexity of the diagnostic system increases
Solution Approach 1:
The diagnostic system segments the biomarker detection into distinct categories (proteins, metabolites, lipids) with specific markers assigned to each category. This segmentation allows for systematic evaluation and interpretation, improving measurement precision while organizing complexity into manageable groups rather than a single undifferentiated panel.
Data Source
AI summary
Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.